CLINICAL_TRIALS ClinicalTrials.gov record update

Does Cryoablation Boost Immune Response Improving the Benefits of Pembrolizumab in Patients With Metastatic or Locally Advanced Triple Negative Breast Cancer?

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06246968
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:47.097681+00:00
Published At: 2025-05-21T00:00:00+00:00
Record Updated At: 2025-05-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Breast Cancer", "Breast Cancer", "Breast Cancer Stage IV", "Triple Negative Breast Cancer", "Triple Negative Breast Neoplasms", "Metastatic Triple-Negative Breast Carcinoma", "Locally Advanced Breast Cancer", "Locally Advanced Triple-Negative Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-05-21"
protocolSection.identificationModule.nctId: "NCT06246968"
protocolSection.identificationModule.officialTitle: "Does Cryoablation Boost Immune Response Improving the Benefits of Pembrolizumab in Patients With Metastatic or Locally Advanced Triple Negative Breast Cancer?"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.